PDF(Pubmed)
Abstract：
BACKGROUND: Thailand has expressed interest in joining the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP), a twelve-country plurilateral trade agreement whose original incarnation included the United States of America (USA). When the USA withdrew from this agreement, key intellectual property clauses relevant to pharmaceuticals were suspended. These could be reinstated should the CPTPP Parties decide to do so.
METHODS: This study uses two scenarios to cost the impact the CPTPP would have had on Thailand\'s 2020 hepatitis C treatment regime if Thailand joined the CPTPP and suspended clauses were reinstated.
RESULTS: Joining the CPTPP could have increased the cost more than tenfold if suspended CPTPP clauses were reinstated and Thailand was not willing or able to issue compulsory licenses. Based on the 2020 budget, the price for this possible scenario could have reduced hepatitis C treatment coverage by 90%.
CONCLUSIONS: Acceding to trade agreements such as the CPTPP that require increasing intellectual property protection, could compromise Thailand\'s hepatitis C program and other national treatment programs reliant on affordable generic medicines. The CPTPP could also prevent Thailand from relying on its own pharmaceutical capabilities to manufacture medicines needed to sustain its treatment programs.
METHODS: This study uses two scenarios to cost the impact the CPTPP would have had on Thailand\'s 2020 hepatitis C treatment regime if Thailand joined the CPTPP and suspended clauses were reinstated.
RESULTS: Joining the CPTPP could have increased the cost more than tenfold if suspended CPTPP clauses were reinstated and Thailand was not willing or able to issue compulsory licenses. Based on the 2020 budget, the price for this possible scenario could have reduced hepatitis C treatment coverage by 90%.
CONCLUSIONS: Acceding to trade agreements such as the CPTPP that require increasing intellectual property protection, could compromise Thailand\'s hepatitis C program and other national treatment programs reliant on affordable generic medicines. The CPTPP could also prevent Thailand from relying on its own pharmaceutical capabilities to manufacture medicines needed to sustain its treatment programs.
摘要：
背景：泰国表示有兴趣加入《全面与进步跨太平洋伙伴关系协定》（CPTPP），由12个国家组成的诸边贸易协定，其最初的化身包括美利坚合众国（美国）。当美国退出这项协议时，与药品相关的关键知识产权条款被暂停。如果CPTPP缔约方决定这样做，这些可以恢复。
方法：本研究使用两种方案来评估如果泰国加入CPTPP并恢复暂停条款，CPTPP对泰国2020年丙型肝炎治疗制度的影响。
结果：如果恢复暂停的CPTPP条款，并且泰国不愿意或不能够颁发强制许可，加入CPTPP可能会使成本增加十倍以上。根据2020年预算，这种可能情况的价格可能会使丙型肝炎治疗覆盖率降低90%.
结论：加入CPTPP等需要加强知识产权保护的贸易协定，可能会损害泰国的丙型肝炎计划和其他依赖负担得起的仿制药的国家治疗计划。CPTPP还可以阻止泰国依靠自己的制药能力来生产维持其治疗计划所需的药物。
方法：本研究使用两种方案来评估如果泰国加入CPTPP并恢复暂停条款，CPTPP对泰国2020年丙型肝炎治疗制度的影响。
结果：如果恢复暂停的CPTPP条款，并且泰国不愿意或不能够颁发强制许可，加入CPTPP可能会使成本增加十倍以上。根据2020年预算，这种可能情况的价格可能会使丙型肝炎治疗覆盖率降低90%.
结论：加入CPTPP等需要加强知识产权保护的贸易协定，可能会损害泰国的丙型肝炎计划和其他依赖负担得起的仿制药的国家治疗计划。CPTPP还可以阻止泰国依靠自己的制药能力来生产维持其治疗计划所需的药物。
